Chronic myeloid leukemia (CML) is a malignant disorder of hematopoietic stem cells. Imatinib mesylate offers clinical benefits during advanced phases of CML, and high rates of complete cytogenetic ...

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in ...